irinotecan has been researched along with oligonucleotides in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chourpa, I; Manfait, M; Millot, JM; Pommier, Y; Riou, JF | 1 |
| Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D | 1 |
| Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R | 1 |
| Becerra, CR; Frenkel, EP; Gaynor, RB; Guo, J; Verma, UN | 1 |
| Liu, WM; Propper, DJ; Scott, KA; Shahin, S | 1 |
| Beck, S; Bourquin, C; Endres, S; Hartmann, G; Schreiber, S | 1 |
| Kobayashi, S; Kumai, T; Matsumoto, N; Nakaya, S; Takeba, Y; Tsuzuki, Y; Yanagida, Y | 1 |
| Asakura, T; Kobayashi, S; Kumai, T; Matsumoto, N; Nakano, H; Nakaya, S; Ohtsubo, T; Sekine, S; Takeba, Y; Tsuzuki, Y; Yanagida, Y | 1 |
| Aladag, N; Aydinlik, S; Ozkan-Ariksoysal, D; Ozsoz, M; Topkaya, SN | 1 |
| Bray, C; Celik, I; Chang, SC; Denne, J; Green, G; Harbison, C; Horak, C; Khambata-Ford, S; Van Cutsem, E; Zhao, L | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Abdullah, S; Abi-Jaoudeh, N; Anderson, V; Duffy, AG; Figg, WD; Fioravanti, S; Greten, TF; Lee, S; Levy, E; MacLeod, AR; Makarova-Rusher, OV; Peer, CJ; Raffeld, M; Rahma, OE; Revenko, AS; Steinberg, SM; Tomita, Y; Trepel, JB; Ulahannan, SV; Walker, M; Wood, BJ | 1 |
1 review(s) available for irinotecan and oligonucleotides
| Article | Year |
|---|---|
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
1 trial(s) available for irinotecan and oligonucleotides
| Article | Year |
|---|---|
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Eukaryotic Initiation Factor-4E; Female; HCT116 Cells; Humans; Irinotecan; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Oligoribonucleotides; RNA, Messenger | 2016 |
10 other study(ies) available for irinotecan and oligonucleotides
| Article | Year |
|---|---|
Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Topics: Camptothecin; DNA Topoisomerases, Type I; DNA, Viral; Hydrolysis; Irinotecan; Kinetics; Lactones; Oligonucleotides; Simian virus 40; Spectrometry, Fluorescence; Topoisomerase I Inhibitors | 1998 |
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2002 |
Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit.
Topics: Agar; Animals; Antineoplastic Agents, Phytogenic; Baculoviral IAP Repeat-Containing 3 Protein; Camptothecin; Caspase 3; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Genes, Reporter; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Mice; Neoplasm Transplantation; NF-kappa B; Oligonucleotides; Proteins; RNA; RNA Interference; RNA, Small Interfering; Time Factors; Transfection; Ubiquitin-Protein Ligases | 2004 |
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
Topics: Base Sequence; Camptothecin; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent Kinases; Etoposide; Flow Cytometry; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Oligonucleotides | 2004 |
Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; CpG Islands; Dendritic Cells; Disease Models, Animal; Female; Fluorouracil; Humans; Immunotherapy; Irinotecan; Mice; Mice, Inbred BALB C; Oligonucleotides | 2006 |
Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; DNA Probes; Electrophoretic Mobility Shift Assay; Humans; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Oligonucleotides; Tumor Suppressor Protein p53 | 2007 |
Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Microscopy, Fluorescence; Oligonucleotides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tumor Suppressor Protein p53 | 2007 |
Different DNA immobilization strategies for the interaction of anticancer drug irinotecan with DNA based on electrochemical DNA biosensors.
Topics: Adsorption; Animals; Antineoplastic Agents; Biosensing Techniques; Camptothecin; DNA; Electrochemistry; Electrodes; Fishes; Graphite; High-Throughput Screening Assays; Irinotecan; Male; Oligonucleotides; Oxidation-Reduction; Sensitivity and Specificity; Spermatozoa; Surface Properties | 2010 |
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Oligonucleotides; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2013 |